Pan-erbB inhibition potentiates BRAF inhibitors for melanoma treatment

The BRAF inhibitor vemurafenib is currently used for treating patients with BRAF V600E mutant melanoma. However, the responses to vemurafenib are generally partial and of relatively short duration. Recent evidence suggests that activation of the epidermal growth factor receptor (EGFR)/erbB signaling...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:Melanoma Res
Hoofdauteurs: Ng, Yuen-Keng, Lee, Jia-Ying, Supko, Kathryn M., Khan, Ayesha, Torres, Salina M., Berwick, Marianne, Ho, Jonhan, Kirkwood, John M., Siegfried, Jill M., Stabile, Laura P.
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: 2014
Onderwerpen:
Article
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4394744/
https://ncbi.nlm.nih.gov/pubmed/24709886
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/CMR.0000000000000060
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items